BioSenic S.A. (0R55.L)

EUR 0.0

(0.0%)

Gross Profit Summary of BioSenic S.A.

  • BioSenic S.A.'s latest annual gross profit in 2023 was 543 Thousand EUR , up 50.0% from previous year.
  • BioSenic S.A.'s latest quarterly gross profit in 2024 Q2 was 1.24 Million EUR , down 0.0% from previous quarter.
  • BioSenic S.A. reported a annual gross profit of 206 Thousand EUR in annual gross profit 2022, down -79.13% from previous year.
  • BioSenic S.A. reported a annual gross profit of 987 Thousand EUR in annual gross profit 2021, down -1.3% from previous year.
  • BioSenic S.A. reported a quarterly gross profit of 1.34 Million EUR for 2024 Q1, up 3161.36% from previous quarter.
  • BioSenic S.A. reported a quarterly gross profit of -44 Thousand EUR for 2023 Q4, down -149.44% from previous quarter.

Annual Gross Profit Chart of BioSenic S.A. (2023 - 2012)

Historical Annual Gross Profit of BioSenic S.A. (2023 - 2012)

Year Gross Profit Gross Profit Growth
2023 543 Thousand EUR 50.0%
2022 206 Thousand EUR -79.13%
2021 987 Thousand EUR -1.3%
2020 1 Million EUR 538.6%
2019 -228 Thousand EUR -122.8%
2018 1 Million EUR 307.9%
2017 -481 Thousand EUR 9.93%
2016 -534 Thousand EUR -36.22%
2015 -392 Thousand EUR 0.0%
2014 - EUR 0.0%
2013 - EUR 0.0%
2012 - EUR 0.0%

Peer Gross Profit Comparison of BioSenic S.A.

Name Gross Profit Gross Profit Difference
Boiron SA 358.08 Million EUR 99.848%
Laboratorios Farmaceuticos Rovi, S.A. 483.34 Million EUR 99.888%
Vetoquinol SA 291.37 Million EUR 99.814%
Valneva SE 52.83 Million EUR 98.972%
AB Science S.A. 587 Thousand EUR 7.496%
Nanobiotix S.A. 42.35 Million EUR 98.718%
PHAXIAM Therapeutics S.A. 1.32 Million EUR 59.05%
Vivoryon Therapeutics N.V. -3.09 Million EUR 117.544%
ABIVAX Société Anonyme 3.91 Million EUR 86.127%
Formycon AG 23.3 Million EUR 97.67%